761 related articles for article (PubMed ID: 28456710)
21. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
[TBL] [Abstract][Full Text] [Related]
22. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha.
Zhang H; Pu J; Qi T; Qi M; Yang C; Li S; Huang K; Zheng L; Tong Q
Oncogene; 2014 Jan; 33(3):387-97. PubMed ID: 23222716
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.
Wu T; Lin Y; Xie Z
Biol Res; 2018 May; 51(1):13. PubMed ID: 29793538
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis
Zhao J; Zhou K; Ma L; Zhang H
Bioengineered; 2020 Dec; 11(1):219-228. PubMed ID: 32083506
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1.
Yu H; Xing H; Han W; Wang Y; Qi T; Song C; Xu Z; Li H; Huang Y
Tumour Biol; 2017 May; 39(5):1010428317701647. PubMed ID: 28459205
[TBL] [Abstract][Full Text] [Related]
27. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
28.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
30. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
31. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
32. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
33. PPP3CB contributes to poor prognosis through activating nuclear factor of activated T-cells signaling in neuroblastoma.
Shakhova I; Li Y; Yu F; Kaneko Y; Nakamura Y; Ohira M; Izumi H; Mae T; Varfolomeeva SR; Rumyantsev AG; Nakagawara A
Mol Carcinog; 2019 Mar; 58(3):426-435. PubMed ID: 30457174
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
35. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH; Horn S; Otto T; Samans B; Heukamp LC; Eilers UC; Krause M; Astrahantseff K; Klein-Hitpass L; Buettner R; Schramm A; Christiansen H; Eilers M; Eggert A; Berwanger B
Int J Cancer; 2008 Feb; 122(3):699-704. PubMed ID: 17943719
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Lin TC; Lin PL; Cheng YW; Wu TC; Chou MC; Chen CY; Lee H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1532-9. PubMed ID: 25990966
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene.
Li H; Sheng Y; Zhang Y; Gao N; Deng X; Sheng X
Gynecol Oncol; 2017 Jun; 145(3):569-576. PubMed ID: 28385388
[TBL] [Abstract][Full Text] [Related]
38. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
39. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
40. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
